Seroprevalence of Infectious Respiratory Agents in Thoroughbred Race Horses at the Seoul Race Park, Republic of Korea

Sang-Kyu Lee1*, Andrew Stephen Waller2, Dongsun Park3

1Veterinary Center, Korea Racing Authority, Gwacheon 13822, Republic of Korea
2Intervacc AB, Hägersten 129 44, Sweden; Department of Biomedical Science and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala 750 07, Sweden
3Department of Biology Education, Korea National University of Education, Cheongju 28173, Republic of Korea

Corresponding
Sang-Kyu Lee, Ph D, DVM
Veterinary Center, Korea Racing Authority, Gwacheon 13822, Republic of Korea
Phone : +82–2–509–2664
E-mail : bestvet@kra.co.kr

INTRODUCTION

Equine infectious respiratory disease is one of the most common causes of lost training days and reduced performance in racehorses, leading to significant financial cost to the equine industry (1, 2). EIV, EHV-1, EHV-4, ERAV, ERBV, and S. equi have been well recognized as causal agents of equine infectious respiratory disease (1-3). EIV of the H3N8 subtype has particularly been considered as the most important respiratory pathogen of horses due to its remarkably contagious nature and ability to spread rapidly through horse populations (4). In contrast, H7N7 viruses have not been isolated for over 20 years and are regarded as extinct (4). Both EHV-1 and EHV-4 are prevalent ubiquitously in horse populations throughout the world and most horses have serological evidence of exposure to these viruses (5).
EHV-1 and EHV-4 can cause respiratory infections characterized by nasal discharge and pyrexia (5). Mild or subclinical infections are common for both viruses (6). Horses are repeatedly infected by both viruses naturally and these viruses can establish life-long latency (6, 7). Transmission can occur through contact with nasal discharge, direct horse to horse contact, aerosol contamination and contact with contaminated feed or equipment (6). ERAV and ERBV are also prevalent worldwide and seropositivity rates in adult horses can approach 100% (8). ERAV and ERBV infection can result in pyrexia, serous nasal discharge, pharyngitis, bronchitis, coughing and swollen lymph nodes (8). However, the severity and frequency of these signs vary and most infections appear to be subclinical (8). Common transmission of both viruses is thought be through contact with nasal secretions and aerosols (8). *Streptococcus equi* subspecies *equi*, the causal agent of strangles, is frequently diagnosed among equine populations worldwide (9, 10). This infection is characterized by enlarged and abscessated mandibular and retropharyngeal lymph nodes (11). Recovered horses can be carriers of *S. equi*, which persistently shed and transmit the organism, without showing obvious clinical signs (10, 11). Subclinical infections as causes of reduced performance in athletic horses have been reported previously (12). Equine infectious respiratory agents can exist in horses without causing obvious clinical signs and so infections can pass unnoticed (8, 10). The absence of EIV and detection of EHV-1, EHV-4, ERAV, ERBV, and *S. equi* using PCR assay in Thoroughbred racehorses in Republic of Korea have been reported (1, 13).

Outbreaks of respiratory disease occur on premise where horses congregate such as racetracks (14). At the SRP, approximately 1,301 Thoroughbred race horses are trained (15) and 865 race games are conducted annually (16). The racehorses are raised and trained closely together at the SRP by sharing of horse management facilities such as horse walkers, swimming pools, and tracks. EIV, EHV-1, EHV-4, ERAV, ERBV, and *S. equi* can be transmitted by direct horse-to-horse contact and aerosolized droplets of nasal secretions (17-19). In particular, outbreaks of EIV, EHV-1, and EHV-4 can cause severe clinical and economic damage to the horse racing industry (20). Therefore, surveillance of these respiratory infectious agents is important for estimating the possible risks and preventing outbreaks of respiratory infectious diseases among racehorses at the SRP.

However, to the authors’ knowledge, serological surveillance has not been conducted in racehorses in Republic of Korea. The aim of this study was to determine the post-vaccination antibody levels to EIV (H3N8), to identify the seroprevalence of EHV-1, EHV-4, ERAV, ERBV and *S. equi* in Thoroughbred racehorses in the SRP and to make recommendations for regular testing in order to prevent possible decreased performance, health status and financial loss.

**MATERIALS AND METHODS**

**Sampling and performance levels**

A total of 94 serum samples were collected from the jugular vein of Thoroughbred racehorses at the Seoul Race Park (SRP) in Republic of Korea using serum separate tubes on race days. Blood samples should be collected for the pre-doping test from all participating racehorses on every race day by the rules of Korea Racing Authority (KRA) and the collected blood samples for the pre-doping test, which were randomly chosen and provide by KRA, were used in this study. The ages of horses ranged from 3 to 6 years old with an average age of 3.4 years old. All horses had previously been vaccinated against EIV using the ProteQFlu EIV vaccine (Merial, France), which contained both H3N8 strain A/eq/Ohio/2003 and H3N8 strain A/eq/Richmond/1/2007, and against strangles using the Equivac® S Strangles Vaccine (Zoetis, Australia), which is cell-free extract of *S. equi*. Horses were examined at sample collection by two experienced regulatory veterinarians for signs of respiratory disease, including nasal discharge, coughing and pyrexia. An examination for lameness was also conducted for all horses and only clinically healthy horses were allowed to participate in races. Only physically sound horses without signs of infectious respiratory disease were included in this study. Serum was separated by centrifugation, heat treated at 56°C for 30 minutes and stored at -20°C until use. The race results on race days were investigated. The race results were divided...
into three performance levels by ratio of ranking (the number of placing / the numbers of participants) in a race: high ≤ 1/3, moderate > 1/3 and ≤ 2/3, low > 2/3. The performance level of the positive and negative groups was compared for each respiratory agent.

Serological tests

The complement fixation (CF) test was performed essentially as described previously by Thomson et al. with modification (21). Briefly, serum were heat inactivated at 60°C for 30 minutes after an initial 1:5 dilution in a CF diluent (1 barbitone CFT diluent tablet, OXOID in 100ml distilled water), which was used as the diluent for all components used in the CF test. Heat inactivated serum was further 2-fold serially diluted with the same volume (25 µl) of CF diluent across 96-well U-shaped-bottom microplates and 25 µl of each virus antigen at known working dilution was then added. Plates were chilled to 4°C and then 25 µl chilled guinea pig complement was added at a dilution of 1 HD_{50} to obtain a working dilution of 3 HD_{50}. A back titration of the complement was performed as a test control. Both the optimum haemolysin and guinea-pig complement dilution had been predetermined by checkerboard titration. Controls for each test serum, RBC's and antigens were also performed. Antigen Plates were incubated overnight at 4°C. The following day plates were incubated for 30 minutes at 37°C before 25 µl of 4% washed sheep RBC sensitized with a working dilution of rabbit haemolysin was added. These plates were incubated for a further 30 minutes and then shaken and stored for 2 hours at 4°C. Dilutions tested in this assay ranged from 1:5 to 1:640. The CF titre was determined as the reciprocal of highest serum dilution reducing hemolysis to 50%. The CF titre was read macroscopically. CF titers ≥ 1:80 were regarded as positive. The dual antigen A & C iELISA test was performed using the commercial Strangles ELISA kit (AHT-SEE-1/3/5, AHT, UK) as described by the manufacturer and Robinson et al. in 2013 (11). The normalized mean OD_{450nm} value ≥ 0.5 was classed as positive. Antibodies against H3N8 strain A/eq/Richmond/1/2007 cultured was measured using the SRH test according to the OIE terrestrial manual 2019 (4). Briefly, virus was coupled to sheep red blood cells (SRBC) with chromium chloride. Agarose plates were made with the sensitized SRBCs and guinea pig complement. Ten microlitres of 56°C heat-inactivated serum was aliquoted into 3 mm wells on the plate and incubated at 34°C for 20-24 hours. Control antiserum against EIV subtype 2 American-like strain A/eq/Richmond/1/2007 from the European Directorate for the Quality of Medicines and Healthcare (Strasbourg, France) was included on each plate as a control. The diameters of the resultant zones of haemolysis were measured with a calibrated viewer. SRH antibody levels were expressed as the area of haemolysis in millimetres squared. The results were interpreted referring to Gildea et al. (22): samples with haemolytic areas of 150 mm² or greater were categorized as virologically protected, samples with antibody levels less than 150 mm², but greater than 85 mm² were categorized as clinically protected, samples with antibody levels less than 85 mm², but greater than 50 mm² were categorized as partially protected and samples with antibody levels less than 50 mm² were categorized as susceptible.

Statistical Analysis

A statistical analysis was performed using the Statistical Package for Social Sciences software, version 22.0 (SPSS Inc., IL, USA). The functions included in the software are Pearson’s chi-squared test (χ²), Fisher’s exact test and linear by linear association. Statistical significance was assessed at ρ < 0.05.

RESULTS

Table 1 summarizes the number of horses with different levels of EIV antibody (<50, 50-85, 85-150 and >150 mm²). Seventy eight out of 94 samples (83.0%) had haemolytic areas over 85 mm², which was interpreted as clinically protected against EIV infection. The results of serological tests for EHV-1, EHV-4, ERAV, ERBV and S. equi are presented in Table 2.
Table 1. Equine influenza H3N8 single radial haemolysis (SRH) levels in SRH Thoroughbred race horses

| SRH               | Number of horses | Mean (mm$^2$) | Median (mm$^2$) |
|-------------------|------------------|---------------|-----------------|
| ≤50 mm$^2$        | 3 (3.2%)         | 30.5          | 44.4            |
| >50 mm$^2$ and ≤85 mm$^2$ | 13 (13.8%)     | 73.6          | 76.2            |
| >85 mm$^2$ and ≤150 mm$^2$ | 65 (69.2%)    | 123.0         | 123.6           |
| >150 mm$^2$      | 13 (13.8%)       | 173.3         | 167.2           |

Table 2. Serology results for respiratory agents in Thoroughbred racehorses in Republic of Korea

| Agent | Test (cut off)       | Positive (n) | Negative (n) | Prevalence (%) |
|-------|----------------------|--------------|--------------|----------------|
| EHV-1 | Complement fixation (≥1:80) | 9            | 85            | 9.6            |
| EHV-4 | Complement fixation (≥1:80) | 29           | 65            | 30.9           |
| ERAV  | Complement fixation (≥1:80) | 1            | 93            | 1.1            |
| ERBV  | Complement fixation (≥1:80) | 1            | 93            | 1.1            |
| S. equi | ELISA (≥0.5)    | 2            | 92            | 2.1            |

Table 3. Performance level between seropositive and negative groups for EHV-1 and EHV-4 in Thoroughbred race horses in Republic of Korea (n=94)

| Performance level | EHV-1 | EHV-4 |
|-------------------|-------|-------|
|                   | Positive (%) | Negative (%) | Positive (%) | Negative (%) |
| High$^a$ and Moderate$^b$ | 3 (33.3%) | 55 (64.7%) | 18 (62.1%) | 40 (61.5%) |
| High$^c, d$       | 1 (11.1%) | 25 (29.4%) | 9 (31.0%) | 17 (26.1%) |
| Moderate$^b, e$   | 2 (22.2%) | 30 (35.3%) | 9 (31.0%) | 23 (35.4%) |
| Low$^f$           | 6 (66.7%) | 30 (35.3%) | 11 (37.9%) | 25 (38.5%) |
| Total             | 9 (100%) | 85 (100%) | 29 (100%) | 65 (100%) |

n, number of horses; EHV, equine herpesvirus; ERA/BV, equine rhinitis virus.

Fig. 1. Performance level between seropositive and negative groups for EHV-1 (A) and EHV-4 (B) in Thoroughbred race horses in Republic of Korea (n=94).
Horses with antibodies to EHV-4 were the most prevalent (30.9%), followed by EHV-1 (9.6%). Six horses were seropositive for both EHV-1 and the EHV-4 CF test (6.4%). However, the prevalence of S. equi, ERAV-, and ERBV-positive horses were too low in this study and the race results were not investigated for those pathogens. The race results were investigated for EHV-1 and EHV-4 positive horses. The SPSS cross table summarizes the relationship between race results and antibodies against EHV-1 and EHV-4 (Table 3). High and moderate performance level in EHV-1 seropositive horses was 33.3% (3 out of 9) and 64.7% (55 out of 85) in the EHV-1 seronegative group. High and moderate performance level was observed for 62.1% (18 out of 29) of the EHV-4 seropositive group and 61.5% (40 out of 65) of the EHV-4 seronegative group. In each case, EHV-1 was not significantly linked to performance level ($p = 0.081$, Fisher’s exact two-sided test). And, EHV-4 was not linked to performance level ($p = 0.789$, Pearson’s chi-squared test). As shown Fig. 1, it seems to have a negative correlation between the race results and antibodies against EHV-1 ($p = 0.080$, linear by linear association), however, the result was not statistically significant ($p > 0.05$). And, in the EHV-4 case, no significant correlation was measured ($p = 0.765$, linear by linear association).

DISCUSSION

Infectious respiratory diseases are important to the training and performance of racehorses (9). In addition to affecting an individual’s athletic performance, outbreaks of acute infectious respiratory disease can lead to the cancellation of race events with huge financial consequences (2). EIV, EHV-1, EHV-4, ERAV, ERBV, and S. equi are important and common infectious respiratory pathogens and can be transmitted by nasal secretion, aerosol and direct contact (17, 19). Racehorses typically have an increased likelihood of developing respiratory infections due to their: relatively young age lacking a fully developed immunity to infectious agents, stabling in large groups, which is favorable for the introduction and exposure to infectious agents and the sharing of facilities in training with increased exposure via aerosols and contaminated surfaces (2). Approximately 1,369 Thoroughbred racing horses at the SRP lived together and had training on a communal race track. Most of the horses at the SRP are a relatively young with an average age of 3.4 years old. Thus, our data suggest that the athletic horses at the SRP are at risk of outbreak or endemic transmission of respiratory pathogens. In 2008, 3 of 72 Thoroughbred racehorses with respiratory disease at the SRP were positive for S. equi by bacterial culture (13). The absence of EIV and existence of EHV-1, EHV-4, ERAV, and ERBV from nasal swabs and serum samples in the SRP has been reported using molecular detection methods in 2013 (1). To the authors’ knowledge, however, few studies conducting serological surveillance for these infectious pathogens have been conducted.

The SRH test has proven to be useful in the serological diagnosis of immunity to EIV infection (4). In the SRH test, the size of haemolytic zone is directly proportional to the level of strain-specific antibody in the serum samples, which correlated closely with protective immunity (23). In this study, the mean SRH level of 120 mm$^2$ was similar to the level of 121 mm$^2$ and 115 mm$^2$ reported for Thoroughbred horses in training in Ireland and the UK respectively (22, 23). Comparing with the previous result of Thoroughbred training horses in Ireland (22), the horses in this study with antibody levels of 85 mm$^2$ or greater, which was interpreted as clinically protected against EIV, was the same at 83.0%. The antibody levels of partially protected horses against EIV was 13.8% (13 out of 94) in this study, while the SRH of Thoroughbred training horses in Ireland was 9.0% (20 out of 223). Like EIV vaccination regulation for Thoroughbred training horses in Ireland (22), all Thoroughbred horses in the SRP are required to be vaccinated at 6 month intervals. Therefore, it is thought that the protective immunity against EIV in Thoroughbred racehorses at the SRP is as high as in other populations of Thoroughbred performance horses.

The CF test, which detects the immunoglobulin M (IgM) antibody for EHV-1 and EHV-4 is also an internationally recognized test and can be used to identify acute infection to both viruses (24). EHV infection induces a short-lived (<3 months) IgM response, followed by a longer-lived (>12 months) IgG response. The CF test is used to measure the short-lived (IgM) antibody response in diagnostic laboratories (24). CF titers increase instantly after infection, peak rapidly,
and then decrease (24). Therefore, a high CF titre in a single serum sample suggests evidence of infection and can be used as initial diagnostic test in EHV cases (24). Seropositivity to EHV-1 and EHV-4 was more common in this study, which is consistent with a previous report in young racehorses (25). The performance levels of EHV-1 and EHV-4 positive and negative groups were compared. There was no significant difference between each EHV-1 and performance levels, and EHV-4 and performance levels. However, there was a trend for EHV-1 to be closely related than EHV-4 ($p = 0.081$ versus $p = 0.789$). The proportion of horses with high and moderate performance levels in the EHV-1 seropositive group (33.3%) was almost significantly less than in the EHV-1 seronegative group (64.7%). The proportion of high and moderate performance levels in the EHV-4 seropositive group was 62.1% versus 61.5% in the EHV-4 seronegative group. Although there are no universally accepted standard definition for poor performance, and noting its multifactorial causes (26), the race result of EHV-1 seropositive group was quite distinctive in the study. EHV-1 infection can be reactivated in horses with latent infection and stress factors such as strenuous physical training, transportation, and fatigue can induce the virus pathogenicity (27). EHV-1 infected horses can have subclinical signs of minimal severity (17), and some horses recovered from EHV-1 respiratory infection may develop a poor performance syndrome (17). High virulence strains of EHV-1 and -4 cause more severe clinical signs (17). In our study, EHV-4 seropositivity was similar in the high, moderate, and low performance groups (31.0%, 31.0%, and 37.9%, respectively). Further, the racehorses at the SRP were considered to be infected with the less virulent EHV-4 strains, and EHV-4 seropositivity did not affect their performance. Our results suggest that subclinical EHV-1 infection may have affected the athletic performance reduction in the racehorses in this study. However, sample size was limited ($n = 94$), and each race had different race level in this study. Therefore, a larger study is now required to confirm this trend.

In a previous study by Black et al., the seroprevalence of ERAV and ERBV in Thoroughbreds in training were relatively high (61% and 77%-86%, respectively) (28). The seroprevalence of $S. equi$ in racehorses was also high (45.7%) in a study conducted in 2017 (29). However, the seropositivity of ERAV, ERBV, and $S. equi$ in Thoroughbred racehorses at the SRP was much lower than that reported in previous studies (1.1%, 1.1%, and 2.1%, respectively). The molecular prevalence of ERAV and ERBV was as low as 2.2% and 6.7%, respectively, in racehorses in Republic of Korea in 2013 (1). Although ERAV and ERBV were present, only a small number of racehorses were infected at the SRP. There is a difference in the test method for $S. equi$. Moghaddam et al. reported a seroprevalence of 45.7% in racehorses during 2017 using an iELISA based on SeM, which is an M-like fibrinogen-binding surface protein of $S. equi$ (29). However, iELISAs using the full SeM protein have been criticised for their inferior specificity due to cross-reactivity with Streptococcus zooepidemicus (18, 30). In 2013, Robinson et al. developed a dual antigen A (N-terminal fragment of SEQ2190) and C (N-terminal fragment of SeM) iELISA kit, which is beneficial in terms of much lower cross-reactivity with $S. zooepidemicus$ (99.3% specificity) and high sensitivity (93.3%) (10, 11, 18). Thus the duplex iELISA kit incorporating SEQ2190 and SeM was used in this study. The difference in cross-reactivity in detecting $S. equi$ using the study method was affected by the lower seropositivity result compared to that reported in a previous study (2.1% versus 45.7%).

In addition, racehorses at the SRP are a closed population and most horses are raised, trained, and raced at the SRP. Biosecurity protocols are performed at the SRP to prevent airborne infectious agents. Disinfection of all the stables and the environment is implemented regularly twice a week. Regular vaccination programs are conducted for all racehorses at the SRP. When entering the SRP, only vaccinated and clinical health certified horses are allowed, while newly imported horses are quarantined and inspected for respiratory clinical signs by veterinary staffs. Therefore, it is thought that the infestation potential of ERAV and $S. equi$ is low due to the closed population with a rigid biosecurity system at the SRP.

Using CF tests and dual antigen ELISA kit for $S. equi$, the recent infection or carrier status of EHV-1, EHV-4, ERAV, ERBV, and $S. equi$ in Thoroughbred racing horses in the SRP have been revealed in this study. High levels of antibodies against EIV linked to regular vaccination was determined through SRH test. Although many racehorses are raised in the SRP and kept in close contact with each other, overall seroprevalence of important respiratory pathogens was relatively low, providing evidence of low risk of respiratory infectious agents in Thoroughbred racehorses in the SRP. EHV-4 was the most prevalent...
pathogen, with 30.9% seropositive horses, and both ERAV and ERBV were the least prevalent at 1.1% in this study. A trend towards reduced performance was found in EHV-1 seropositive racehorses in this study. Further studies are required to confirm the relationship between the EHV-1 infection and sub-optimal athletic performance in racehorses.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was declared.

ACKNOWLEDGEMENTS

We are grateful to Ms Toni-Ann Hammond and Dr Adam Rash for helping in serological tests.

REFERENCES

1) Ko S, Kang JG, Yeh JY, Moon JS, Choi GC, Won S, et al. First Report on Molecular Detection of Equine Upper Respiratory Infectious Viruses in Republic of Korea. J Equine Vet Sci 2013;33:628-36.

2) Morley PS, Pusteria N. Viral respiratory disease in athletic horses. In: Hinchcliff KW, Kaneps AJ, Geor RJ, editors. Equine Sports Medicine and Surgery: Basic and clinical sciences of the equine athlete 2 ed, London: Elsevier Health Sciences; 2014. p.649-60.

3) Back H, Weld J, Walsh C, Cullinane A. Equine Rhinitis A Virus Infection in Thoroughbred Racehorses-A Putative Role in Poor Performance? Viruses 2019;11:963.

4) OIE. 2019. Equine influenza (Infection with equine influenza virus). In: OIE Terrestrial Manual 2019. World Organization for Animal Health, Paris, France, Available at https://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/3.06.07_EQ_INF.pdf. (accessed March 22, 2022).

5) Patel JR, Heldens J. Equine herpesvirus 1 (EHV-1) and 4 (EHV-4)--epidemiology, disease and immunoprophylaxis: a brief review. Vet J 2005;170:14-23.

6) Yildirim Y, Yilmaz V, Kirmizigul AH. Equine herpes virus type 1 (EHV-1) and 4 (EHV-4) infections in horses and donkeys in northeastern Turkey. Iran J Vet Res 2015;16:341-4.

7) OIE. 2018. Equine rhinopneumonitis (Infection with equid herpesvirus-1 and -4). In: OIE terrestrial manual 2018. World Organization for Animal Health, Paris, France, Available at https://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/3.06.09_EQUINE_RHINO.pdf. (accessed March 22, 2022).

8) Horsington J, Lynch SE, Gilkerson JR, Studdert MJ, Hartley CA. Equine picornaviruses: well known but poorly understood. Vet Microbiol 2013;167:78-85.

9) NAHMS. 2001. Infectious Upper Respiratory Disease in U.S. Horses: Disease Frequency. In: USDA, Available at https://www.aphis.usda.gov/animal_health/nahms/equine/downloads/equine98/Equine98_is_IURD.pdf. (accessed 22 March, 2022).

10) Scott Pirie R. One is good ... two are better: breaking the ‘stranglehold’ of asymptomatic carriers on Streptococcus equi dissemination? Vet J 2013;197:527-8.

11) Robinson C, Steward KF, Potts N, Barker C, Hammond TA, Pierce K, et al. Combining two serological assays optimises sensitivity and specificity for the identification of Streptococcus equi subsp. equi exposure. Vet J 2013;197:188-91.
12) Fraipont A, Van Erck E, Ramery E, Richard E, Denoix JM, Lekeux P, et al. Subclinical diseases underlying poor performance in endurance horses: diagnostic methods and predictive tests. *Vet Rec* 2011;169:154.

13) Ryu SH, Koo HC, Park YK, Kim JM, Jung WK, Davis WC, et al. Etiologic and immunologic characteristics of thoroughbred horses with bacterial infectious upper respiratory disease at the Seoul Race Park. *J Microbiol Biotechnol* 2009;19:1041-50.

14) Traub-Dargatz JL, Dargatz DA, Morley PS, Dwyer R, Landry K. Infection control strategies for horses in the new millennium. *AAEP* 2001;47:36-40.

15) Korea Racing Authority. Thoroughbred report, 2022 Available at https://studbook.kra.co.kr/neweng/html/eng_bhr_reg_tonggye3.jsp (accessed March 22, 2022).

16) Korea Racing Authority. KRA racing statistics, 2022 Available at https://race.kra.co.kr/globalEn/racingStatistic.do (accessed March 22, 2022).

17) Slater J. Equine Herpesviruses. In: Sellon DC, Long MT, editors. Equine Infectious Diseases 2nd ed, St. Louis, USA: W.B. Saunders; 2013. p.151-68.

18) Boyle AG. *Streptococcus equi* ss *equi*. In: Pusterla N, Higgins J, editors. Interpretation of Equine Laboratory Diagnostics 1st ed, Hoboken, USA: Wiley; 2018. p.165-9.

19) Waller AS, Sellon DC, Sweeney CR, Timoney PJ, Newton JR, Hines MT. Streptococcal Infections. In: Sellon DC, Long MT, editors. Equine Infectious Diseases 2nd ed, St. Louis, USA: W.B. Saunders; 2013. p.265-77.

20) Sack A, Cullinane A, Daramragchaa U, Chuluunbaatar M, Gonchigoo B, Gray GC. Equine Influenza Virus—A Neglected, Reemergent Disease Threat. *Emerg Infect Dis* 2019;25:1185-91.

21) Thomson GR, Mumford JA, Campbell J, Griffiths L, Clapham P. Serological detection of equid herpesvirus 1 infections of the respiratory tract. *Equine Vet J* 1976;8:58-65.

22) Gildea S, Arkins S, Cullinane A. A comparative antibody study of the potential susceptibility of Thoroughbred and non-Thoroughbred horse populations in Ireland to equine influenza virus. *Influenza Other Respir Viruses* 2010;4:363-72.

23) Newton JR, Townsend HG, Wood JL, Sinclair R, Hannant D, Mumford JA. Immunity to equine influenza: relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/Equine-2 viruses (H3N8). *Equine Vet J* 2000;32:65-74.

24) Crossley B, Hill A. Alpha-Herpesviruses (EHV-1, EHV-4). In: Pusterla N, Higgins J, editors. Interpretation of Equine Laboratory Diagnostics 1st ed, Hoboken, USA: Wiley; 2018. p.153-4.

25) Wood JLN, Newton JR, Chanter N, Mumford JA. Inflammatory airway disease, nasal discharge and respiratory infections in young British racehorses. *Equine Vet J* 2005;37:236-42.

26) Back H, Penell J, Pringle J, Isaksson M, Ronéus N, Treiberg Berndtsson L, et al. A longitudinal study of poor performance and subclinical respiratory viral activity in Standardbred trotters. *Vet Rec Open* 2015;2:e000107.

27) Khusro A, Aarti C, Rivas-Caceres RR, Barbabosa-Pliego A. Equine Herpesvirus-I Infection in Horses: Recent Updates on its Pathogenicity, Vaccination, and Preventive Management Strategies. *J Equine Vet Sci* 2020;87:102923.

28) Black WD, Wilcox RS, Stevenson RA, Hartley CA, Ficorilli NP, Gilkerson JR, et al. Prevalence of serum neutralising antibody to equine rhinitis A virus (ERAV), equine rhinitis B virus 1 (ERBV1) and ERBV2. *Vet Microbiol* 2007;119:65-71.

29) Moghaddam S, Shayeigh J, Hassanpour A. Seroprevalence of *Streptococcus equi* subsp. *equi* in racing horses. *Online J Vet Res* 2017;21:559-63.

30) Ivens PAS, Pirie S. *Streptococcus equi* subspecies *equi* diagnosis. *Equine Vet J* 2021;53:15-7.